Dentsply Sirona today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries, and a current member of the board of directors of Dentsply Sirona, has been appointed president and chief executive officer, effective August 1, 2025. He succeeds Simon Campion, who is leaving the company on July 31, 2025.
Scavilla recently served as president and chief executive officer of Globus Medical, where he led the acquisition of NuVasive and oversaw the integration of the two organizations to create the second-largest spine technology company in the world. Prior to joining Globus Medical, he spent 28 years in a variety of financial and operational leadership roles at Johnson & Johnson. Scavilla was appointed to the Dentsply Sirona board in February 2025.
Gregory T. Lucier, chairman of the board, said, “Dan’s appointment as CEO underscores the board’s strong and unwavering commitment to delivering enhanced value to shareholders and positioning Dentsply Sirona for future success. Dan is a seasoned healthcare veteran, and we’re confident that his three decades of executive leadership experience and disciplined focus on commercial growth, product innovation, and financial and operational excellence make him well-suited to lead the company into its next chapter. There is significant untapped opportunity across the dental market, and we believe that Dan is the right leader to help accelerate the company’s business transformation, reposition Dentsply Sirona as an industry leader, and deliver long-term value creation.”
“Dentsply Sirona is a company that I have admired for its trusted brands, and since joining the board in February, I have gained an even deeper appreciation for the enormous potential of our business, people, and products,” Scavilla said. “The board and I are aligned in our belief that, while our ongoing transformation is yielding results, there is more we can do to drive improved commercial, operational, and financial performance across the organization. As I step into the CEO role, I look forward to working with the team to continue the company’s transformation, drive sustained profitable growth, and enhance value for all stakeholders.”
Lucier continued, “On behalf of the board of directors, I want to thank Simon for his contributions to our company, laying a strong foundation for continued success while upholding high integrity and transparency. We appreciate his commitment to Dentsply Sirona and wish him all the best in his future endeavors.”
“It has been a privilege to serve as CEO over the past three years. While we have had to address a number of challenges, Dentsply Sirona now has a strong foundation in place, and I fully expect the company will reach new heights under Dan’s leadership,” Campion said.
In conjunction with the leadership transition, Campion has stepped down from the Dentsply Sirona board. Scavilla, who will continue to serve as a director, will no longer serve on the board’s audit and finance committee.
About Daniel Scavilla
Scavilla most recently served as president and CEO of Globus Medical, Inc. (NYSE: GMED), where he led the acquisition of NuVasive, Inc. in an all-stock deal valued at $3 billion and oversaw the integration of the two organizations to create the world’s second-largest spine technology company. He previously held various executive leadership positions at Globus Medical, including chief financial officer; executive vice president; chief commercial officer; and president, trauma, where he scaled the company’s manufacturing and distribution capabilities and launched the orthopedics and trauma business unit.
Prior to joining Globus Medical, Scavilla spent 28 years in leadership roles across different businesses at Johnson & Johnson. Notably, in his role as chief financial officer and worldwide vice president of finance at Advanced Sterilization Products, he helped the company’s infection prevention business capture the top market position in sterilization. Scavilla currently serves on the Dentsply Sirona board and expects to resign as a director at Globus Medical. He received a bachelor of science in finance and organizational behavior from LaSalle University and a master of business administration in international management from Temple University.
About Dentsply Sirona
Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands.
Dentsply Sirona’s innovative products provide high-quality, effective, and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The company’s shares are listed in the United States on Nasdaq under the symbol XRAY.
Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
DISCLAIMER
This information and any attachment thereto contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance. These forward-looking statements reflect views and assumptions regarding expectations and projections about future events and are based on currently available information or information available on the date of any document incorporated by reference. You can generally identify these forward-looking statements by the use of words such as “may,” “could,” “estimate,” “will,” “believe,” “anticipate,” “think,” “intend,” “expect,” “project,” “plan,” “target,” “forecast,” and similar words and expressions. However, these words are not the exclusive means of identifying such statements.
In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances are forward-looking statements and may include statements relating to future revenues, expenses, margins, profitability, net income/(loss), earnings per share, and other measures of results of operations and the prospects of future growth of our business. These forward-looking statements are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. For a discussion of such risks, uncertainties, and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental products and services, pricing, future sales volume of the company’s products, the possibility of changing economic, market, and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, our ability to integrate the businesses of Dentsply Sirona, acquisitions and affiliations, readers are urged to carefully review and consider various disclosures made by the company and Dentsply Sirona in their public filings, including in their annual reports on Form 10-K and in their reports on Forms 10-Q and 8-K filed with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. Except as required by law, the company does not assume any obligation to update any forward-looking statements contained in this document or the attachments to reflect new information or future events or developments after the date any such statement is made.
Registered brands, trade names, and logos are used. Even in particular cases, when they appear without a ™ or ®, all corresponding legal rules and provisions apply. All rights are retained by Dentsply Sirona. Clinicians may have been compensated for use of their experiences and testimonials.
